Ironwood Pharmaceuticals Inc. is a biotechnology company dedicated to discovering, developing, and commercializing therapies for gastrointestinal (GI) and select rare diseases. Headquartered in the US with operations in Switzerland, the company applies deep GI expertise to build a portfolio of innovative medicines and expand treatment options for patients with significant unmet needs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ironwood is focused its research and development strategy on leveraging its expertise in gastrointestinal (GI) and rare diseases to bring medicines to patients. The company has dedicated significant resources to the research, development, and commercialization of linaclotide, as well as other programs, including apraglutide. The company is actively exploring ways to enhance the clinical profile of LINZESS, its commercial product, by studying linaclotide in additional indications, populations, and formulations. Additionally, Ironwood Pharmaceuticals Inc is advancing apraglutide through clinical trials for the treatment of short bowel syndrome with intestinal failure (SBS-IF) and has ongoing early research and development efforts focused on supporting its development-stage GI and rare diseases programs. The R&D unit of the company is responsible for managing the company's research and development activities, which include expenses incurred in connection with the research into and development of products and product candidates. These activities encompass compensation, benefits, and other employee-related expenses, research and development-related facility costs, third-party contract costs relating to nonclinical study and clinical trial activities, development of manufacturing processes, regulatory registration of third-party manufacturing facilities, and licensing fees for product candidates. In FY2025, the company spent US$95.1 million on its R&D activities, which as a percentage of revenue stood at 32.1%, and declined 14.6% YoY. As of December 2025, the company has a linaclotide patent portfolio composed of 11 US patents, four European patents, 10 Japanese patents, one Chinese patent, 46 patents in other foreign jurisdictions, and numerous pending applications. The apraglutide patent portfolio includes one issued US patent and 58 foreign patents.